|
|
(One intermediate revision not shown.) |
Line 3: |
Line 3: |
| <StructureSection load='2dp7' size='340' side='right'caption='[[2dp7]], [[Resolution|resolution]] 1.55Å' scene=''> | | <StructureSection load='2dp7' size='340' side='right'caption='[[2dp7]], [[Resolution|resolution]] 1.55Å' scene=''> |
| == Structural highlights == | | == Structural highlights == |
- | <table><tr><td colspan='2'>[[2dp7]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2DP7 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2DP7 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[2dp7]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2DP7 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2DP7 FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CMY:(6-AMINOHEXYL)CARBAMIC+ACID'>CMY</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.55Å</td></tr> |
- | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=DU:2-DEOXYURIDINE-5-MONOPHOSPHATE'>DU</scene></td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CMY:(6-AMINOHEXYL)CARBAMIC+ACID'>CMY</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene></td></tr> |
- | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[2dpb|2dpb]], [[2dpc|2dpc]]</td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2dp7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2dp7 OCA], [https://pdbe.org/2dp7 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2dp7 RCSB], [https://www.ebi.ac.uk/pdbsum/2dp7 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2dp7 ProSAT]</span></td></tr> |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2dp7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2dp7 OCA], [http://pdbe.org/2dp7 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2dp7 RCSB], [http://www.ebi.ac.uk/pdbsum/2dp7 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=2dp7 ProSAT]</span></td></tr> | + | |
| </table> | | </table> |
| <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
Line 23: |
Line 22: |
| </StructureSection> | | </StructureSection> |
| [[Category: Large Structures]] | | [[Category: Large Structures]] |
- | [[Category: Ito, T]] | + | [[Category: Ito T]] |
- | [[Category: Juan, E C.M]] | + | [[Category: Juan ECM]] |
- | [[Category: Kondo, J]] | + | [[Category: Kondo J]] |
- | [[Category: Kurihara, T]] | + | [[Category: Kurihara T]] |
- | [[Category: Matsuda, A]] | + | [[Category: Matsuda A]] |
- | [[Category: Takenaka, A]] | + | [[Category: Takenaka A]] |
- | [[Category: Ueno, Y]] | + | [[Category: Ueno Y]] |
- | [[Category: B-dna]]
| + | |
- | [[Category: Dna]]
| + | |
- | [[Category: Modified nucleotide]]
| + | |
| Structural highlights
Publication Abstract from PubMed
Oligonucleotides containing 5-(N-aminohexyl)carbamoyl-modified uracils have promising features for applications as antigene and antisense therapies. Relative to unmodified DNA, oligonucleotides containing 5-(N-aminohexyl)carbamoyl-2'-deoxyuridine ((N)U) or 5-(N-aminohexyl)carbamoyl-2'-O-methyluridine ((N)U(m)), respectively exhibit increased binding affinity for DNA and RNA, and enhanced nuclease resistance. To understand the structural implications of (N)U and (N)U(m) substitutions, we have determined the X-ray crystal structures of DNA:DNA duplexes containing either (N)U or (N)U(m) and of DNA:RNA hybrid duplexes containing (N)U(m). The aminohexyl chains are fixed in the major groove through hydrogen bonds between the carbamoyl amino groups and the uracil O4 atoms. The terminal ammonium cations on these chains could interact with the phosphate oxygen anions of the residues in the target strands. These interactions partly account for the increased target binding affinity and nuclease resistance. In contrast to (N)U, (N)U(m) decreases DNA binding affinity. This could be explained by the drastic changes in sugar puckering and in the minor groove widths and hydration structures seen in the (N)U(m) containing DNA:DNA duplex structure. The conformation of (N)U(m), however, is compatible with the preferred conformation in DNA:RNA hybrid duplexes. Furthermore, the ability of (N)U(m) to render the duplexes with altered minor grooves may increase nuclease resistance and elicit RNase H activity.
Crystal structures of DNA:DNA and DNA:RNA duplexes containing 5-(N-aminohexyl)carbamoyl-modified uracils reveal the basis for properties as antigene and antisense molecules.,Juan EC, Kondo J, Kurihara T, Ito T, Ueno Y, Matsuda A, Takenaka A Nucleic Acids Res. 2007;35(6):1969-77. Epub 2007 Mar 6. PMID:17341465[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Juan EC, Kondo J, Kurihara T, Ito T, Ueno Y, Matsuda A, Takenaka A. Crystal structures of DNA:DNA and DNA:RNA duplexes containing 5-(N-aminohexyl)carbamoyl-modified uracils reveal the basis for properties as antigene and antisense molecules. Nucleic Acids Res. 2007;35(6):1969-77. Epub 2007 Mar 6. PMID:17341465 doi:gkl821
|